We canât show the full text here under this license. Use the link below to read it at the source.
GLP-1 receptor agonists and pulmonary hypertension in diabetes: A promising therapeutic strategy
Using GLP-1 receptor activators as a possible treatment for lung blood pressure problems in diabetes
AI simplified
Abstract
GLP-1 receptor agonists may reduce pulmonary hypertension incidence in diabetic patients.
- GLP-1 receptor agonists exhibit anti-inflammatory and vasodilatory effects.
- These agents are associated with improvements in pulmonary artery pressure.
- Vascular remodeling and cardiopulmonary load may also improve with GLP-1 receptor agonist use.
- Data from a Veterans Affairs cohort supports a lower incidence of pulmonary hypertension among GLP-1 receptor agonist users.
- Further prospective trials are needed to confirm these findings and optimize treatment strategies.
AI simplified